Skip to main content
SpringerLink
Log in

Clinical Investigation of Medicinal Products for the Treatment of Migraine

  • Commentary
  • Published:
International Journal of Pharmaceutical Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias, and facial pain. Cephalalgia 1992; 12: 229–37

    Article  Google Scholar 

  2. International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine. 2nd ed. Cephalalgia 2000; 20: 765–86

    Article  Google Scholar 

  3. The European Medicine Evaluation Agency (EMEA). Notes for guidance on clinical investigation of medicinal products for the treatment of migraine. CPMP/EWP/788/01 [online]. Available from URL: http://www.emea.eu.int/ [Accessed 2002 Sep 19]

  4. The Headache Impact TestTM [online]. Available from URL: http://www.headachetest [Accessed 2003 Aug 19]

  5. The Headache Impact TestTM [online]. Available from URL: http://www. amihealthy.com/Static/HITInfo.asp /Static/HITInfo.asp [Accessed 2003 Aug 19]

  6. Quality of Life SF-36 Form [online]. Available from URL: http://www.sf36.com [Accessed 2003 Aug 19]

  7. Kilminster SG, Mould P. Comparison of the internal reliability and validity of the McGill Pain Questionnaire and Short Pain Inventory. Int J Pharm Med 2002; 16: 87–95

    Google Scholar 

  8. Kilminster SG, Dowson A, Bundy M. The Headache Impact Test and Short Pain Inventory: outcome measures compared. Int J Pharm Med 2003; 17: 23–32

    Google Scholar 

  9. Stewart WF, Lipton RB, Kolodner K, et al. Reliability of the migraine disability assessment score (MIDAS) in a population based sample of migraine sufferers. Cephalalgia 1999; 19: 107–14

    Article  PubMed  CAS  Google Scholar 

  10. Stewart WF, Lipton RB, Simon D, et al. Validity of an illness severity measure of headache in a population sample of migraine sufferers. Pain 1999; 79: 291–301

    Article  PubMed  CAS  Google Scholar 

  11. Stewart WF, Lipton RB, Whyte J, et al. An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology 1999; 53: 988–94

    Article  PubMed  CAS  Google Scholar 

  12. Jhingram P, Osterhaus JT, Miller DW, et al. Development and validation of migraine-specific quality of life questionnaire. Headache 1998; 38: 295–302

    Article  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.

Author information

Authors and Affiliations

  1. Society of Pharmaceutical Medicine, London, UK

    Shaun Kilminster

  2. Neuroscience Centre, King’s College Hospital, London, UK

    Andrew Dowson

  3. Sanofi-Synthelabo, Paris, France

    Donna Ellender

Authors
  1. Shaun Kilminster
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew Dowson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Donna Ellender
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kilminster, S., Dowson, A. & Ellender, D. Clinical Investigation of Medicinal Products for the Treatment of Migraine. Int J Pharm Med 17, 113–115 (2003). https://doi.org/10.1097/00124363-200317030-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1097/00124363-200317030-00002

Keywords

Search

Navigation